Patents by Inventor Chiao-Rou LIU

Chiao-Rou LIU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for treating oral cancers
    Patent number: 11304939
    Abstract: Provided herein is a method for treating an oral cancer in a subject. According to embodiments of the present disclosure, the method comprises respectively obtaining a first and a second biological samples from a lesion site and a non-lesion site of the subject; respectively measuring the expression levels of CHEK1, PIK3CA, or PIK3CD in both biological samples by qRT-PCR thereby obtaining a first and a second expression level; determining the ratio of the first to the second expression level; and administering to the subject an effective amount of a checkpoint kinase 1 inhibitor when the ratio for CHEK1 is at least 1.7 or a phosphatidylinositol 3-kinase inhibitor when the ratio for PIK3CA is at least 2.4, or when the ratio for PIK3CD is at least 3.1.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: April 19, 2022
    Assignees: CHANG GUNG UNIVERSITY, CHANG GUNG MEMORIAL HOSPITAL, LINKOU
    Inventors: Chia-Yu Yang, Kai-Ping Chang, Chia-Hsun Hsieh, Chih-Ching Wu, Chun-Nan Ouyang, Chiao-Rou Liu
  • METHODS FOR TREATING ORAL CANCERS
    Publication number: 20210353605
    Abstract: Provided herein is a method for treating an oral cancer in a subject. According to embodiments of the present disclosure, the method comprises respectively obtaining a first and a second biological samples from a lesion site and a non-lesion site of the subject; respectively measuring the expression levels of CHEK1, PIK3CA, or PIK3CD in both biological samples by qRT-PCR thereby obtaining a first and a second expression level; determining the ratio of the first to the second expression level; and administering to the subject an effective amount of a checkpoint kinase 1 inhibitor when the ratio for CHEK1 is at least 1.7 or a phosphatidylinositol 3-kinase inhibitor when the ratio for PIK3CA is at least 2.4, or when the ratio for PIK3CD is at least 3.1.
    Type: Application
    Filed: May 14, 2020
    Publication date: November 18, 2021
    Applicants: Chang Gung University, Chang Gung Memorial Hospital, Linkou
    Inventors: Chia-Yu YANG, Kai-Ping CHANG, Chia-Hsun HSIEH, Chih-Ching WU, Chun-Nan OUYANG, Chiao-Rou LIU